Sun, May 19, 2024
[Archive]
Volume 15, Issue 1 ( March 2023 2023)
Iranian Journal of Blood and Cancer 2023, 15(1): 1-9 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Hassani A, Asaadi Tehrani G, Zahmatkesh N, Mirzaahmadi S. Evaluation the Effect of Chemotherapy Drugs and Thiosemicarbazone Complexes on the Expression of URHC and CASC15 LncRNAs in Acute Lymphoblastic Leukemia Cell Line. Iranian Journal of Blood and Cancer 2023; 15 (1) :1-9
URL: http://ijbc.ir/article-1-1310-en.html
URL: http://ijbc.ir/article-1-1310-en.html
1- Department of Genetics, Zanjan Branch, Islamic Azad University, Zanjan, Iran
2- Department of Genetics, Zanjan Branch, Islamic Azad University, Zanjan, Iran , Golnaz_ asaadi¬ @yahoo.com
2- Department of Genetics, Zanjan Branch, Islamic Azad University, Zanjan, Iran , Golnaz_ asaadi¬ @yahoo.com
Abstract: (699 Views)
Background: Acute lymphoblastic leukemia (ALL) is a common type of leukemia in children, accounting for about 30% of pediatric malignancies. Researchers aimed to assess the impact of chemotherapy drugs and Thiosemicarbazone complexes on the expression of URHC and CASC15 LncRNAs in Jurkat E6.1 cell line, which represents Acute Lymphoblastic Leukemia. Thiosemicarbazone complexes are a group of chemical compounds known for their antitumor activities.
Material and Methods: Optimal doses of chemotherapy drugs and thiosemicarbazone complexes were prepared and administered to the cell line at different time points (24, 48, and 72 hours). RNA extraction and cDNA synthesis were performed, and the expression of URHC, CASC15, and GAPDH genes was measured using Real-time PCR. Statistical analysis was conducted on the obtained results.
Results: The study found that complex 3, a combination of two chemotherapy drugs (Cytarabine and 6MP) at specific concentrations (1 mM and 5 mM, respectively), significantly reduced the expression of URHC after 72 hours. Similarly, treatment with Arac at 5 mM for 72 hours showed the most effective concentration and time for decreasing the expression of CASC15 LncRNAs.
Conclusion: In conclusion, the research demonstrated that the studied drugs had a positive impact on reducing the expression of CASC15 and URHC onco-lncRNAs. However, the optimal effects varied depending on the concentrations and treatment durations. These findings highlight the potential of the examined drugs in targeting specific LncRNAs associated with Acute Lymphoblastic Leukemia.
Subject:
Adults Hematology & Oncology
Received: 2023/01/10 | Accepted: 2023/03/12 | Published: 2023/03/30
Received: 2023/01/10 | Accepted: 2023/03/12 | Published: 2023/03/30
References
1. Pui CH CD PD, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. Med. 2009;360(26):2730-41. [DOI:10.1056/NEJMoa0900386]
2. Kantarjian HM OBS ST, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol. 2000;18(3):547-61. [DOI:10.1200/JCO.2000.18.3.547]
3. abbour E OBS KM, Kantarjian H. New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia. Cancer. 2015;121(15):2517-28. [DOI:10.1002/cncr.29383]
4. Jemal A TR MT, et al. Cancer Statistics. Cancer J Clin. 2004;54(1):8-29. [DOI:10.3322/canjclin.54.1.8]
5. Siegel RL MK JA. Cancer statistics. Clin. 2015;65(1):5-29. [DOI:10.3322/caac.21254]
6. Thilini R. Fernando JRC, Matteo Zampini, Norma I. Rodriguez-Malave, Michael O. Alberti, Jaime Anguiano, Tiffany M. Tran, Jayanth K. Palanichamy, Jasmine Gajeton, Nolan M. Ung, Cody J. Aros, Ella V. Waters, David Casero, Giuseppe Basso, Martina Pigazzi & Dinesh S. Rao. The lncRNA CASC15 regulates SOX4 expression in RUNX1-rearranged acute leukemia. Molecular Cancer. 2017;16(1):126.
7. Xu WH ZJ DZea. Long non-coding RNA URHC regulates cell proliferation and apoptosis via ZAK through the ERK/MAPK signaling pathway in hepatocellular carcinoma. Biol.2014;10(7):664-76. [DOI:10.7150/ijbs.8232]
8. Yang B JC, Wang J, Guo X, Chen Y, Xu R, Peng L, Liu J, Li L Identification of microRNAs associated with lymphangiogenesis in human gastric cancer. Clin Transl Oncol. 2014;16:374-9. [DOI:10.1007/s12094-013-1081-6]
9. Lee HJ KJ KK, et al. Genotoxic stress/p53-induced DNAJB9 inhibits the pro-apoptotic function of p53. Cell Death Differ. 2015;22(1):86-95. [DOI:10.1038/cdd.2014.116]
10. Kurisu J HA MH, et al. MDG1/ERdj4, an ER-resident DnaJ family member, suppresses cell death induced by ER stress. Genes Cells. 2003;8(2):189-202. [DOI:10.1046/j.1365-2443.2003.00625.x]
11. Schreffler CSaS. Cyclophosphamide. Encyclopedia of Toxicology. 2014;1:709-11.
12. Chabner BA R, D.P., Paz-Ares, L., Carbonero, R.G., Calabresi, P. Antineoplastic Agents. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 2001:1389-459.
13. Prodanowich FM JRT, C. Pezon, T. Fasihi, and R. S. Kirsner. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol. 2005;52: 262-7. [DOI:10.1016/j.jaad.2004.06.017]
14. J. Neradil GP aRV. New mechanisms for an old drug; DHFR- and nonDHFR-mediated effects of methotrexate in cancer cells. Europepmc. 2012;25 2S87-92.
15. J. Cudmore MS JS, and R. Zarychanski. Methotrexate and trimethoprimsulfamethoxazole: toxicity from this combination continues to occur. Can Fam Physician. 2014;60: 53-6.
16. Hiroyuki Imanishi NO, Mariko Yagi , Yukari Noro , Yuka Moriya , Tsutomu Nakamura , Akira Hayakawa , Yasuhiro Takeshima , Toshiyuki Sakaeda , Masafumi Matsuo , Katsuhiko Okumura Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma. Hum Genet. 2007;52(2):166-71. [DOI:10.1007/s10038-006-0096-z]
17. Lobana TS, Sharma, R., Bawa, G. and Khanna, S. Bonding and Structure Trends of Thiosemicarbazone Derivatives of Metals-An Overview. Coordination Chemistry. 2009;253:977-1055. [DOI:10.1016/j.ccr.2008.07.004]
18. Richardson DSKaDR. The Evolution of Iron Chelators for the Treatment of Iron Overload Disease and Cancer. Pharmacological Reviews. 2005;57 (4):547-83. [DOI:10.1124/pr.57.4.2]
19. A Garoufis SH, N Hadjiliadis. Palladium coordination compounds as anti-viral, anti-fungal, anti-microbial and anti-tumor agents. Coordination Chemistry Reviews. 2009;253:1384-97. [DOI:10.1016/j.ccr.2008.09.011]
20. Mehmet Aslantaş EK, Necmettin Demir, Ali E Şabik, Mehmet Tümer, Metin Kertmen. Synthesis, spectroscopic, structural characterization, electrochemical and antimicrobial activity studies of the Schiff base ligand and its transition metal complexes. Molecular and Biomolecular Spectroscopy. 2009;74:617-24. [DOI:10.1016/j.saa.2009.07.006]
21. Seyed Abolfazl Hosseini-Yazdi AMa AAKa, Václav Eigner b,Michal Dušek b, Majid Mahdavi c, Sina Soltani c, Farzaneh Lotfipour d, Jonathan White. Reactions of copper(II), nickel(II), and zinc(II) acetates with a new water-soluble 4-phenylthiosemicarbazone Schiff base ligand: Synthesis, characterization, unexpected cyclization, antimicrobial, antioxidant, and anticancer activities. Polyhedron. 2017;124:156-65. [DOI:10.1016/j.poly.2016.12.004]
22. Guo Z-L, Richardson DR, Kalinowski DS, Kovacevic Z, Tan-Un KC, Chan GC-F. The novel thiosemicarbazone, di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC), inhibits neuroblastoma growth in vitro and in vivo via multiple mechanisms. Journal of hematology & oncology. 2016;9(1):1-16. [DOI:10.1186/s13045-016-0330-x]
23. Sardroud SJ, Hosseini-Yazdi SA, Mahdavi M, Poupon M, Skorepova E. Synthesis, characterization and in vitro evaluation of anticancer activity of a new water-soluble thiosemicarbazone ligand and its complexes. Polyhedron. 2020;175:114218. [DOI:10.1016/j.poly.2019.114218]
24. Karp JE, Giles FJ, Gojo I, Morris L, Greer J, Johnson B, Thein M, Sznol M, Low J. A Phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine®) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders. Leukemia research. 2008;32(1):71-7. [DOI:10.1016/j.leukres.2007.05.003]
25. Li M-X, Chen C-L, Ling C-S, Zhou J, Ji B-S, Wu Y-J, Niu J-Y. Cytotoxicity and structure-activity relationships of four α-N-heterocyclic thiosemicarbazone derivatives crystal structure of 2-acetylpyrazine thiosemicarbazone. Bioorganic & medicinal chemistry letters. 2009;19(10):2704-6. [DOI:10.1016/j.bmcl.2009.03.135]
26. Qiong Wu SX JM, Pingping Hui, Ting Wang, Wenying Meng, Min Shi, and Yugang Wang Long non‐coding RNA CASC15 regulates gastric cancer cell proliferation, migration and epithelial mesenchymal transition by targeting CDKN1A and ZEB1. Mol Oncol. 2018 12(6):799-813. [DOI:10.1002/1878-0261.12187]
27. Liang Sheng RW. Long Non-Coding RNA-CASC15 Promotes Cell Proliferation, Migration, and Invasion by Activating Wnt/β-Catenin Signaling Pathway in Melanoma. Pathobiology. 2020;87(1):20-9. [DOI:10.1159/000502803]
28. Grasedieck S, Ruess C, Krowiorz K, Lux S, Pochert N, Schwarzer A, Klusmann J-H, Jongen-Lavrencic M, Herold T, Bullinger L. The long non-coding RNA Cancer Susceptibility 15 (CASC15) is induced by isocitrate dehydrogenase (IDH) mutations and maintains an immature phenotype in adult acute myeloid leukemia. haematologica. 2020;105(9). [DOI:10.3324/haematol.2019.235291]
29. Z-G Gu G-HS J-HL, W-X Huang, Z-H Qian, J Qiu. Effects of long non-coding RNA URHC on proliferation, apoptosis and invasion of colorectal cancer cells. Eur Rev Med Pharmacol Sci. 2018;22:1658-64.
30. Wei-Hua Xu J-BZ ZD, Xiao Li , Ti Zhou , Jie Liu , De-Sheng Wang , Wen-Jie Song , Ke-Feng Dou . Int J . 10.(7). Long non-coding RNA URHC regulates cell proliferation and apoptosis via ZAK through the ERK/MAPK signaling pathway in hepatocellular carcinoma. Biol Sci. 2014 10(7):664-76. [DOI:10.7150/ijbs.8232]
31. kunwei niu SQ, Xuan Zhang, Jimin Dai, Jianlin Wang, Ye Nie, Hong Zhang, Kaishan Tao, Wenjie Song. LncRNA URHC promotes cell proliferation by regulating a miR-5007-3p/DNAJB9 axis in hepatocellular carcinoma. 2020.
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
- Iranian Journal of Blood and Cancer
- Journal Tel: +989369936116
- Publisher Tel: +982122275917
- Mail: Info@ijbc.ir
